ResearcherUniversity of California, Los AngelesNo recent work listed
Alexandra M. Moore
Matched on ORCID iD 0000-0002-9555-2339; OpenAlex author ID A5059419248. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 35
2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper
Papers 5
- Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
- NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. Co-author DOI 10.1073/pnas.2012469118↗
- Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. First author DOI 10.1016/j.surg.2019.12.008↗
- Pancreatic Cancer. Co-author DOI 10.1001/jama.2019.14699↗
- Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. Co-author DOI 10.1073/pnas.1812410116↗
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Timothy R. Donahue · 5 shared papers, 2019–2022 · strength 0.58
- Paper Pancreatic Cancer. DOI 10.1001/jama.2019.14699↗
- Paper Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoad… DOI 10.1016/j.surg.2021.10.015↗
- Paper NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. DOI 10.1073/pnas.2012469118↗
- Shimpei Maeda · 2 shared papers, 2020–2022 · strength 0.21
- Paper Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoad… DOI 10.1016/j.surg.2021.10.015↗
- Paper Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatodu… DOI 10.1016/j.surg.2019.12.008↗
- Mark D. Girgis MD · 2 shared papers, 2020–2022 · strength 0.21
- Paper Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoad… DOI 10.1016/j.surg.2021.10.015↗
- Paper Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatodu… DOI 10.1016/j.surg.2019.12.008↗
- Irmina A. Elliott · 2 shared papers, 2019–2021 · strength 0.17
- Evan R. Abt · 2 shared papers, 2019–2021 · strength 0.17
- Razmik Ghukasyan · 2 shared papers, 2019–2021 · strength 0.17
- Caius Gabriel Radu · 2 shared papers, 2019–2021 · strength 0.17
- Zev A. Wainberg · 1 shared paper, 2022 · strength 0.12
- Carlos F. Fernandez-del Castillo · 1 shared paper, 2022 · strength 0.12
- Michael A. Mederos · 1 shared paper, 2022 · strength 0.12
- Jin Peng He · 1 shared paper, 2022 · strength 0.12
- Lingdi Yin · 1 shared paper, 2022 · strength 0.12
- William R. Burns · 1 shared paper, 2022 · strength 0.12
- Sami Shoucair · 1 shared paper, 2022 · strength 0.12
- Joon Y. Park · 1 shared paper, 2022 · strength 0.12
- Richard Andrew Burkhart · 1 shared paper, 2022 · strength 0.12
- Jun Yu · 1 shared paper, 2022 · strength 0.12
- Christopher L. Wolfgang · 1 shared paper, 2022 · strength 0.12
- Motaz Qadan · 1 shared paper, 2022 · strength 0.12
- Cristina Rosa Ferrone · 1 shared paper, 2022 · strength 0.12
- Keith D. Lillemoe · 1 shared paper, 2022 · strength 0.12
- Oscar Joe Hines · 1 shared paper, 2022 · strength 0.12
- Akhil Chawla · 1 shared paper, 2022 · strength 0.12
- Keke Liang · 1 shared paper, 2021 · strength 0.10
- Jing Cui · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.